John G McHutchison

Summary

Affiliation: Gilead Sciences
Country: USA

Publications

  1. pmc Metaprotein expression modeling for label-free quantitative proteomics
    Joseph E Lucas
    Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA
    BMC Bioinformatics 13:74. 2012
  2. doi request reprint The role of genetic markers in hepatitis C virus therapy: a major step for individualized care
    John G McHutchison
    Gilead Sciences, Foster City, CA, USA
    Liver Int 31:29-35. 2011
  3. ncbi request reprint The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients
    Heather M Patton
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 40:484-90. 2004
  4. ncbi request reprint Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies
    Paul J Pockros
    Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 47:174-82. 2007
  5. doi request reprint Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients
    Aesop Cho
    Gilead Sciences, 333 Lakeside Drive, Foster City, California 94044, United States
    J Med Chem 57:1812-25. 2014
  6. pmc Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy
    Evguenia S Svarovskaia
    Gilead Sciences, Inc, Foster City, CA, USA
    J Clin Microbiol 50:3267-74. 2012
  7. doi request reprint Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin
    Charlotte Hedskog
    Gilead Sciences, Inc, Foster City, CA
    Hepatology 61:471-80. 2015
  8. doi request reprint Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study
    Anuj Gaggar
    Gilead Sciences, Inc, Foster City, CA, USA Electronic address
    Vaccine 32:4925-31. 2014
  9. doi request reprint Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials
    Evguenia S Svarovskaia
    Gilead Sciences, Foster City
    Clin Infect Dis 59:1666-74. 2014
  10. doi request reprint Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist
    Uri Lopatin
    Gilead Sciences, Foster City, CA, USA
    Antivir Ther 18:409-18. 2013

Collaborators

Detail Information

Publications11

  1. pmc Metaprotein expression modeling for label-free quantitative proteomics
    Joseph E Lucas
    Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA
    BMC Bioinformatics 13:74. 2012
    ..Additionally, there may be systematic shifts in the sensitivity of the machine between experiments or even through time within the duration of a single experiment...
  2. doi request reprint The role of genetic markers in hepatitis C virus therapy: a major step for individualized care
    John G McHutchison
    Gilead Sciences, Foster City, CA, USA
    Liver Int 31:29-35. 2011
    ..They also provide the framework and potential for a clinically relevant and meaningful pharmacogenomic approach to personalizing anti-HCV treatment...
  3. ncbi request reprint The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients
    Heather M Patton
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 40:484-90. 2004
    ..Questions remain regarding the etiology of steatosis in hepatitis C, and its impact on disease progression and treatment outcomes...
  4. ncbi request reprint Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies
    Paul J Pockros
    Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 47:174-82. 2007
    ..To explore safety, pharmacokinetics, and pharmacodynamics of oral administration of resiquimod, a Toll-like receptor 7 and 8 agonist that induces endogenous interferon-alpha, in subjects with chronic hepatitis C virus infection...
  5. doi request reprint Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients
    Aesop Cho
    Gilead Sciences, 333 Lakeside Drive, Foster City, California 94044, United States
    J Med Chem 57:1812-25. 2014
    ..In a phase I clinical study, the potential for potent activity was demonstrated but with high intra- and interpatient pharmacokinetic and pharmacodynamic variability. ..
  6. pmc Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy
    Evguenia S Svarovskaia
    Gilead Sciences, Inc, Foster City, CA, USA
    J Clin Microbiol 50:3267-74. 2012
    ..6 to 3.8 log(10) with NS3 protease inhibitor monotherapy that does not suppress the identified preexisting NS3 DRMs and thus a need for a combination therapy...
  7. doi request reprint Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin
    Charlotte Hedskog
    Gilead Sciences, Inc, Foster City, CA
    Hepatology 61:471-80. 2015
    ..Eleven of these twelve patients were treated with a regimen for genotype 2 HCV infection, but responded as if they had genotype 1 infection; 1 patient had received placebo...
  8. doi request reprint Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study
    Anuj Gaggar
    Gilead Sciences, Inc, Foster City, CA, USA Electronic address
    Vaccine 32:4925-31. 2014
    ..GS-4774 is being developed as a therapeutic vaccine for chronic HBV infection. The aim of this study was to assess the safety, tolerability and immunogenicity of GS-4774 in healthy subjects...
  9. doi request reprint Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials
    Evguenia S Svarovskaia
    Gilead Sciences, Foster City
    Clin Infect Dis 59:1666-74. 2014
    ..Sofosbuvir resistance is primarily conferred by the S282T substitution in NS5B...
  10. doi request reprint Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist
    Uri Lopatin
    Gilead Sciences, Foster City, CA, USA
    Antivir Ther 18:409-18. 2013
    ..The aim of this double-blind, placebo-controlled, single ascending-dose study was to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GS-9620 in healthy volunteers...
  11. ncbi request reprint A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    Hepatology 37:1368-74. 2003
    ..In conclusion, IL-12 as monotherapy at the doses used in this trial for chronic hepatitis C has low efficacy, was poorly tolerated, and is unlikely to provide an alternative to conventional IFN-based therapy...